ROR1 and CD3 Therapeutic Pair (ROR1 x CD3)

In applied immunotherapy, "ROR1 and CD3" refers not to a unique biomolecule but to a *therapeutic strategy* where agents (such as bi-specific antibodies) simultaneously bind ROR1 on cancer cells and CD3 on T cells. This strategy aims to induce specific T cell-mediated killing of ROR1-expressing cancer cells by co-localizing effector T cells to malignant targets through the CD3/TCR complex. While ROR1 and CD3 are distinct proteins, they are commonly referenced as a 'target pair' in the context of bi-specific antibody therapeutics.

Other names

ROR1-CD3 bispecific targetROR1/CD3BiTE target (ROR1 x CD3)

Bi-specific antibodies simultaneously bind ROR1 on cancer cells and CD3 on T cells, inducing specific T cell-mediated killing of ROR1-expressing cancer cells by co-localizing effector T cells to malignant targets through the CD3/TCR complex. This re-directs the T cell's cytotoxic activity against the tumor cell.